New Risk • May 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 15% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (89% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$87m net loss in 3 years). Announcement • Apr 21
Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 26, 2026 Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 26, 2026. Announcement • Apr 09
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 Study of IKT-001 for Pulmonary Arterial Hypertension Inhibikase Therapeutics, Inc. announced that the first patient has been enrolled in the Company’s pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). IKT-001 is a novel oral prodrug of imatinib mesylate designed to reduce gastrointestinal side effects commonly observed with imatinib. Under the revised pivotal Phase 3 design, as confirmed in the written responses received from the FDA, Inhibikase has adopted an adaptive study design and a 12-week dose-titration phase to allow for optimized dosing. The global IMPROVE-PAH trial is a two-part adaptive Phase 3 study. Part A of IMPROVE-PAH is a double blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance at Week 24. Part B of IMPROVE-PAH seamlessly begins following the last patient in Part A being enrolled and adopts an identical format to Part A, except the primary endpoint will be change in 6-minute walk distance at Week 24 in approximately 346 patients. The Phase 3 study protocol also permits a sample size re-estimation for Part B based on Part A findings, if necessary. IMPROVE-PAH is expected to be conducted in up to approximately 180 sites around the world. New Risk • Jan 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$83m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Dec 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$87m net loss in 3 years). New Risk • Dec 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 80% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$78m net loss in 3 years). Announcement • Nov 22
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension Inhibikase Therapeutics, Inc. announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in PAH. The Phase 3 study, named IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is expected to be initiated in the first quarter of 2026. IKT-001 is an investigational novel pro-drug of imatinib mesylate ("imatinib"). Imatinib is an anti-proliferative tyrosine kinase inhibitor, TKI, with potential best-in-class improvements in pulmonary Vascular resistance ("PVR") and 6-minute walk distance ("6MWD") of 45 meters(1) based on Phase 3 IMPRES and Phase 2 studies(2). Despite the IMPRES Phase 3 study of imatinib demonstrating improved exercise capacity and hemodynamics in patients with advanced PAH, high discontinuations impacted the results. IKT-001 is a prodrug of imatinib which is engineered to realize the potential of imatinib in PAH and lower discontinuations in the upcoming Phase 3 study. The Company previously planned to initiate a Phase 2b study in 150 subjects in PAH prior to advancing to a pivotal Phase 3 study. However, the Company submitted a Type C Meeting request to the U.S. Food & Drug Administration ("FDA") to, among other things, obtain feedback on an immediate transition to a pivotal Phase 3 study design. Following receipt from the FDA of the Written Response from the Type C interaction, the Company now plans to initiate a two-part adaptive Phase 3 study. The company expects Part A of IMPROVE-PAH will be a double blind, placebo-controlled study in 140 patients with a primary endpoint of PVR at Week 24. The company expects Part B will adopt an identical format to Part A except the primary endpoint will be 6MWD at Week 24 in 346 patients. The company believe this adaptive Phase 3 study design has important advantages including; permitting a 12-week dose-titration phase designed to get patients to the highest tolerable dose of IKT-001; uninterrupted enrollment between Part A and Part B; and the ability to, if necessary, undertake a sample size re-estimation for Part B based on Part A findings. Given the Company was well-advanced in initiating the previous Phase 2b study design, the Company expects to initiate IMPROVE-PAH in the first quarter of 20 26, with this study expected to be conducted in up to approximately 180 sites around the world. Board Change • Aug 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Director Mark Iwicki was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 20
Inhibikase Therapeutics Announces Appointment of Timothy Pigot as Chief Commercial and Strategy Officer Inhibikase Therapeutics, Inc. announced the appointment of veteran biopharma executive Timothy Pigot as the Company’s Chief Commercial and Strategy Officer. Mr. Pigot is an accomplished pharmaceutical industry executive with over three decades of experience in both large pharma and start up organizations. Most recently he served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company’s therapeutic candidate in PAH. Previously Mr. Pigot was Vice President of Marketing for MyoKardia, where he led commercial launch strategy for mavacamten, a first in class cardiac myosin inhibitor. Earlier in his career, Mr. Pigot held several leadership positions at Gilead Sciences and Pfizer, where he led sales, marketing, and operations for products in the PAH, cardiopulmonary, CNS and oncology therapeutic areas. Mr. Pigot earned his Bachelor of Sciences degree from the SUNY Binghamton School of Management. Announcement • Jun 21
Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • May 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 26% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 26% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$59m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Announcement • May 06
Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 27, 2025 Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 27, 2025. New Risk • Apr 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Announcement • Feb 25
Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) acquired CorHepta Pharmaceuticals, Inc. for $14.8 million. Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) acquired CorHepta Pharmaceuticals, Inc. for $14.8 million on February 21, 2025. The consideration consists of 4,979,101 shares of the Company’s common stock, to the former stockholders of CorHepta, of which 3,319,397 were issued as upfront consideration. 82,979 Consideration Shares of the Upfront Consideration were deposited in a twelve-month escrow for purposes of satisfying potential indemnity obligations of the CorHepta Stockholders under the Merger Agreement. The remaining Consideration Shares were issued as contingent consideration, which will vest upon achievement of a certain milestone. If the vesting condition is not satisfied as of the first anniversary of the Closing Date, then the Contingent Consideration will be forfeited.
Inhibikase Therapeutics, Inc. (NasdaqCM:IKT) completed the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025. New Risk • Feb 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$531k). Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Revenue is less than US$1m (US$1.0 revenue). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Announcement • Feb 24
Inhibikase Therapeutics, Inc. Announces Management Appointments Inhibikase Therapeutics, Inc. announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (PAH) to its senior leadership team. Chris Cabell, M.D., former Chief Medical Officer of Arena Pharmaceuticals and Chief Executive Officer of CorHepta Pharmaceuticals, Inc. (CorHepta) has been appointed as President and Head of Research & Development. Additionally, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, John Adams, Ph.D. has been appointed Chief Scientific Officer. Vince Aurentz to join Inhibikase board of directors. Chris Cabell, MD MHS FACC., – Dr. Cabell is a cardiologist and joins Inhibikase from CorHepta, where he was Chief Executive Officer. Previously, Dr. Cabell was Chief Medical Officer at Arena Pharmaceuticals, Zura Bio, and Emergent Bio Solutions. Dr. Cabell has also served on multiple corporate and scientific advisory boards. Earlier in his career Dr. Cabell was a consultant, founding HD Consulting and serving as Head of the Therapeutic & Specialty Business Development team for Quintiles. Dr. Cabell is board certified in both internal medicine and cardiology. He is an honors graduate of The Pennsylvania State University and Duke University, where he completed his medical degree, residency in Internal Medicine, fellowship in Cardiology and a master’s degree in Health Sciences. He is also a Fellow of the American College of Cardiology. John Adams, Ph.D, – Dr. Adams joins Inhibikase from CorHepta where he was co-founder and Chief Scientific Officer. Previously he was Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals, and the Head of Research at Arena Pharmaceuticals. Dr. Adams earned his PhD in Physiological Science at UCLA and his B.S. Biological Sciences from U.C. Santa Barbara. Announcement • Jan 31
Inhibikase Therapeutics, Inc. Reports Results from the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease On January 29, 2025, Inhibikase Therapeutics, Inc. (the “Company”) reported results from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial enrolled 126 people with untreated Parkinson’s disease who were, on average, 14 months from diagnosis and were dosed in equal proportions at 50 mg, 100 mg, 200 mg or placebo for 12 weeks. The primary endpoints of this trial were safety and tolerability and there were 15 secondary endpoints to evaluate treatment benefit. The 201 Trial met its primary endpoint of safety and tolerability, with 95% of enrolled participants completing 12 weeks on risvodetinib. Risvodetinib adverse event observations were comparable to placebo in frequency and severity. There were no treatment-related severe adverse events. In the hierarchy of 15 secondary functional assessments, risvodetinib treatment did not demonstrate an improvement in the top hierarchical efficacy measure, which was the sum of Parts 2 and 3 of the Movement Disorder Society Universal Parkinson’s Disease Rating Scale (“MDS-UPDRS”) at any dose group (50mg, 100mg or 200mg) versus placebo. Risvodetinib demonstrated an improvement at 100 mg in Part 2 of the MDS-UPDRS of -1.41 points (nominal p=0.036, 95% CI (-2.27, -0.096)), and at 50 mg in the Schwab& England Activities of Daily Life Scale of +4% (nominal p=0.0004, 95% CI (+1.3%, +6.7%)). Analysis of alpha-synuclein pathology using skin biopsy suggests a treatment dependent reduction in neuronal alpha-synuclein deposition in cutaneous nerve fibers across all doses. Data will be presented at a future medical meeting. The Company will pause further development of risvodetinib as it focuses its resources on advancing lead program IkT-001Pro in pulmonary arterial hypertension (“PAH”) and will consider its strategic options for the risvodetinib program. New Risk • Dec 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$531k). Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Revenue is less than US$1m (US$1.0 revenue). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). New Risk • Nov 17
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$531k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$531k). Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Revenue is less than US$1m (US$1.0 revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Reported Earnings • Nov 17
Third quarter 2024 earnings released: US$0.65 loss per share (vs US$0.86 loss in 3Q 2023) Third quarter 2024 results: US$0.65 loss per share. Net loss: US$5.78m (loss widened 26% from 3Q 2023). Revenue is forecast to grow 88% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. New Risk • Oct 27
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Revenue is less than US$1m (US$80k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$21.5m market cap). Board Change • Oct 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. Independent Director Dennis Berman was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 22
Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors On October 21, 2024, the company has closed the transaction. Announcement • Oct 11
Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors Inhibikase Therapeutics, Inc. announced that it entered into a securities purchase agreement and will receive $109,982,165 in funding led by new investor Soleus Capital, with participation from new investors including Sands Capital, Fairmount, Blackstone Multi-Asset Investing, Commodore Capital, Perceptive Advisors, ADAR1 Capital Management, BSQUARED Capital, Nantahala Capital, Stonepine Capital Management and Spruce Street Capital on October 9, 2024. The company will be issuing 58,310,000 shares at an issue price $1.37, pre-funded warrants to purchase up to an aggregate of 21,985,000 shares of common stock, along with accompanying Series A-1 warrants to purchase an aggregate of 40,139,474 shares of common stock and accompanying Series B-1 warrants to purchase an aggregate of 73,813,529 shares of common stock. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable at any time after their original issuance and will not expire. The Series A-1 Warrants have an exercise price of $1.37 per share and the Series B-1 Warrants have an exercise price of $1.49 per share. The purchase price for each pre-funded warrant and accompanying warrants is $1.369. The transaction is expected to close on October 21, 2024, subject to customary closing conditions. Announcement • Oct 10
Inhibikase Therapeutics, Inc. Announces Board Changes Inhibikase Therapeutics, Inc. announced that two current members of the Board of Directors, Ms. Gisele Dion and Dr. Paul Grint, will resign and four new directors will join the Company's board: Roberto Bellini (former Chief Executive of BELLUS Health Inc. and current Managing Partner of BSQUARED Capital), Amit Munshi (current Chief Executive of Orna Therapeutics and former CEO of Arena Pharmaceuticals), Arvind Kush (current CFO of Candid Therapeutics and former CFO of RayzeBio) and David Canner (Partner at Soleus Capital). In addition, Mr. Bellini will serve as Independent Chairperson of the Board of Directors. Reported Earnings • Aug 16
First half 2024 earnings released: US$1.39 loss per share (vs US$2.08 loss in 1H 2023) First half 2024 results: US$1.39 loss per share (improved from US$2.08 loss in 1H 2023). Net loss: US$9.61m (loss narrowed 6.3% from 1H 2023). Revenue is forecast to grow 81% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Announcement • Aug 07
Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Inhibikase Therapeutics, Inc. announced that they will report Q2, 2024 results After-Market on Aug 14, 2024 Announcement • Jun 06
Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline Inhibikase Therapeutics, Inc. announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs. Complete The 201 Trial in untreated Parkinson’s disease. The Company anticipates that the last patient will complete the 12-week treatment period before the close of the third quarter of 2024. The Company expects to report biomarker and outcome data to support the Company’s pursuit of an End of Phase 2 and Phase 3 protocol discussion with the FDA by the end of 2024. Expansion into cardiopulmonary disease. Following the Company’s pre-IND meeting with the FDA, the Company will submit its IND application to the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension (PAH) early in the third quarter of 2024, opening a new therapeutic area for the Company. The active ingredient in IkT-001Pro, imatinib, has previously been shown to be disease-modifying for PAH. The Company believes that 001Pro could have a more favorable safety and tolerability profile compared to imatinib for this indication. If approved, IkT-001Pro could be a branded product with all the value drivers of a novel treatment for indication of high unmet need. The IND for 001Pro in PAH represents the seventh the Company has filed since 2019. Scaling manufacturing of IkT-001Pro. Following the Company’s pre-NDA meeting with the FDA in January, 2024, the Company is scaling its process development efforts for IkT-001Pro to support late-stage clinical development and NDA batch requirements. These activities include development of new dosage forms to differentiate 001Pro tablets from generic imatinib mesylate in alignment with FDA feedback. Seeking support for the 202 Trial in Multiple System Atrophy through the Other Transaction Authority of NINDS. The National Institute of Neurological Diseases and Stroke (NINDS) is initiating a new funding mechanism for clinical development in neuroscience beginning June, 2024. Through this new program, termed the Other Transaction Authority (OTA), the Company is seeking to support its Phase 2 ‘202 Trial’ in MSA trial using a dedicated U.S. trial network set-up by the Institute. Discontinuing antiviral development for Progressive Multifocal Leukoencephalopathy (PML): As part of the Company’s strategy to focus on late-stage clinical assets in neurodegeneration, cancer and cardiopulmonary disease, Inhibikase will discontinue development of treatments for PML. Announcement • May 21
Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million. Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 714,527
Security Name: Class B warrants
Security Type: Equity Warrant
Securities Offered: 957,925
Transaction Features: Registered Direct Offering Reported Earnings • May 17
First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023) First quarter 2024 results: US$0.73 loss per share. Net loss: US$4.65m (loss widened 3.8% from 1Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Announcement • May 16
Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering. Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,968,254
Security Name: Common Warrants
Security Type: Equity Warrant
Securities Offered: 3,968,254
Security Name: Pre-funded Warrants
Security Type: Equity Warrant
Securities Offered: 3,968,254 Announcement • May 10
Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension Inhibikase Therapeutics, Inc. announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application. In the final minutes from the pre-IND meeting, the FDA agreed that Inhibikase had built a bridge between imatinib’s use in blood and gastrointestinal cancers and PAH and supported the Company’s Phase 2/3 design as the initial clinical pursuit. The FDA requested the Company complete a pre-clinical cell culture-based study of the hERG ion channel to compare Pro to imatinib as Imatinib has previously been linked with certain cardiovascular abnormalities. The Company intends to complete this 7-day experiment prior to an IND submission. In parallel, the Company has initiated discussions with potential strategic partners in order to advance the development of Pro for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension is a rare disease of the pulmonary microvasculature. PAH can arise spontaneously, or can be caused by genetic mutations, drugs or environmental toxins. PAH is also associated with connective tissue disease (CTD), congenital heart disease and HIV infection. Most treatments for PAH attempt to address symptoms of this progressive disorder, but the recent approval of Winrevair® highlights that disease-modification is possible. There are approximately 30,000 cases of PAH in the U.S. The global PAH market size was valued at $7.66 billion in 2023 and is estimated to grow at a compound annual growth rate of 5.4% between 2024 to 2030. Announcement • Apr 28
Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024, at 16:00 US Eastern Standard Time. Agenda: To elect one director to the Board of Directors of the Company (the “Board of Directors”) to serve as a Class I director, to serve until the Company’s 2027 annual meeting of stockholders, or until his successor is duly elected and qualified; to ratify the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 2,500,000 shares to replenish the number of authorized shares of common stock available for future grants; to approve an amendment to Article XII of Amended and Restated Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof; and to transact other business. New Risk • Apr 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.87m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (US$261k revenue). Market cap is less than US$10m (US$8.87m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (34% increase in shares outstanding). Announcement • Apr 04
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension Inhibikase Therapeutics, Inc. announced that the Company will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) in the Division of Cardiology and Nephrology (DCN) at the U.S. Food and Drug Administration (FDA) for a Pre-IND meeting to discuss IkT-001Pro (“Pro”) as a treatment for Pulmonary Arterial Hypertension (PAH). The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes. Pulmonary Arterial Hypertension is a rare disease of the pulmonary microvasculature. PAH can arise spontaneously, or can be caused by genetic mutations, drugs or environmental toxins. PAH is also associated with connective tissue disease (CTD), congenital heart disease, HIV infection and other insults that could affect the right side of the heart. Most treatments for PAH attempt to address symptoms of this progressive disorder, but the recent approval of Winrevair® highlights that disease-modification is possible. There are approximately 30,000 cases of PAH in the U.S. The global PAH market size was valued at $7.66 billion in 2023 and is estimated to grow at a compound annual growth rate of 5.4% between 2024 to 2030. Imatinib has been shown to have efficacy on par with Winrevair® (doi: 10.1164/rccm.201001-0123OC), however its side effect profile precluded approval in this patient population. Changes in the standard-of-care for these patients suggests that the serious adverse events which arose from treatment with imatinib mesylate in the 2010s may not occur when imatinib is delivered as IkT-001Pro; the Company has yet to conduct any clinical studies to validate this hypothesis. The Pre-IND meeting will review our proposed late-stage trial design to reproduce efficacy and evaluate the safety and tolerability of imatinib delivered by IkT-001Pro in patients with WHO Class I PAH, as well as seek regulatory advice or clarity on FDA orange book exclusivity, approval pathways, special designations. Based on the meeting outcome, the Company will evaluate whether to proceed with filing the IND for IkT-001Pro in this indication and undertake a strategic review and business development initiative to define the Company’s path forward with this product. Reported Earnings • Mar 28
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$3.57 loss per share. Net loss: US$19.0m (loss widened 5.4% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Announcement • Mar 08
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders Inhibikase Therapeutics, Inc. will present an update on the of the 201 Trial evaluating risvodetinib at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal. Dr. Werner's presentation entitled "The 201 Trial in Untreated Parkinson's Disease" will be presented at the Symposium on "Advances in Parkinson's Disease and Dementia with Lewy Body Drug Development" to be held on March 9, 2024 at 6:25 pm WEST /1:25 pm EDT. The 201 Trial is evaluating 50, 100 and 200 mg once daily doses of risvo in untreated Parkinson's disease. As of February 24, 2024, 32 sites are open and actively evaluating prospective trial participants. 59 participants have been enrolled, 19 prospective participants are in medical screening and 54 potential participants are being evaluated for suitability to initiate medical screening. Participants experience in the trial appears to be positive, as clinician and patient impression of disease status or severity is not changing over the 12 week course of dosing. Motor and non-motor functional assessments cannot be interpreted from blinded results. Depending on the date of enrollment of the last participant, top line results from the 201 Trial might be reported in the second-half of 2024. Announcement • Feb 02
Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million. Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • Jan 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. Revenue is less than US$1m (US$324k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Shareholders have been diluted in the past year (47% increase in shares outstanding). Market cap is less than US$100m (US$13.3m market cap). Major Estimate Revision • Jan 18
Consensus revenue estimates increase by 44% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$180.0k to US$260.0k. Forecast losses expected to reduce from -US$4.39 to -US$3.69 per share. Biotechs industry in the US expected to see average net income growth of 8.6% next year. Consensus price target of US$27.00 unchanged from last update. Share price rose 26% to US$1.74 over the past week. Announcement • Jan 17
Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024 Inhibikase Therapeutics, Inc. announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024. The Company’s Vice-President for Finance, Garth Lees-Rolfe, will be promoted to Chief Financial Officer. Announcement • Dec 21
Inhibikase Therapeutics, Inc. Provides Update on Development Programs Inhibikase Therapeutics, Inc. issued a Letter to Shareholders. What a ride it has been in 2023. The year began with a quick recovery in January from a brief clinical hold for risvodetinib as well as the successful closing of a $10 million equity raise to support the advancement of neurodegenerative and cancer therapeutics programs. Based on the current pace of enrollment, the expect to report results from this trial in the second half of 2024. approach with Multiple System Atrophy, an aggressive form of Parkinson's disease, has seen similar success in 2023. The company opened an IND for direct entry into a Phase 2 clinical trial and have received Orphan Drug Designation for risvodetinIB as a treatment for MSA from the FDA, although the trial start date is yet to be determined. The company plan to submit complementary regulatory documents for risvodet in non-oncology indications to which imatinib has already been shown to have meaningful benefit. The company look forward to providing updates on this progress in the first half of 2024. Across the therapeutic pipeline, the company have developed technologies that will advance clinical development and may augment commercial success. For risvodetinib, a commercial tablet formulation was developed that doubles drug exposure at the same dose. The company believe this formulation significantly improves oral drug absorption. As always, transparency remains a core principle. Announcement • Dec 05
Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro Inhibikase Therapeutics, Inc. announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate. The Company expects to provide an update following the meeting. The 501 bioequivalence study evaluated IkT-001Pro at four single ascending doses of 300, 400, 500 and 600 mg in 27 healthy subjects ranging in age from 18 to 55, followed by a pivotal phase comparing the 600 mg of IkT-001Pro to 400 mg imatinib mesylated in 31 healthy volunteers. Pharmacokinetic profiles for imatinib delivered by IkT-001Pro and imatinib mesylate were similar at equivalent doses. Imatinib mesylate is currently approved for treatment of Philadelphia chromosome positive chronic myelogenous leukemia and acute lymphoblastic leukemia, adults with myelodysplastic or myeloproliferative disease associated with mutations in the c-Kit gene and stomach cancers that arise from mutations in the c-Kit or PDGFR genes. About IkT-001Pro: IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec®?). Imatinib is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations found in the bone marrow or for gastrointestinal cancers that arise from c-Kit and/or PDGFRa/b mutations in the stomach; c-Kit, PDGFRa/b and Abelson are all members of the Abelson Tyrosine Kinases protein family. IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in stable-phase CML and/or reduce the relapse rate for these patients. In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in non-human primates, reducing burdensome gastrointestinal side effects that occur following oral administration. Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018. Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022) Third quarter 2023 results: US$0.86 loss per share. Net loss: US$4.60m (loss widened 2.2% from 3Q 2022). Revenue is expected to decline by 107% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%. Announcement • Nov 08
Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Inhibikase Therapeutics, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023 Announcement • Oct 17
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment Inhibikase Therapeutics, Inc. highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson’s disease. These participants were withdrawn from the trial following the FDA’s temporary clinical hold in November, 2022 that was lifted in January, 2023. The Company also provided an update on the enrollment progress and recruitment tools being used in the ongoing 201 Trial. In August 2023, Inhibikase presented an analysis of the primary and secondary endpoints performed on these eleven participants at the Movement Disorders Society Congress. Eight participants were on active drug (three at 50 mg, two at 100 mg and three at 200 mg) and three were given placebo. The primary endpoints were safety and tolerability and no participant experienced any clinically significant adverse events. The Company also detailed changes in the functional assessments of motor and non-motor features using a hierarchical analysis of fifteen secondary endpoints. The study evaluated non-motor function, such as activities of daily living, using the MDS-UPDRS Part 2 score and evaluated motor function using the MDS-UPDRS Part 3 score. The sum of these scores is the top functional readout in the hierarchy. Clinical improvement might be concluded if the End of Study score is lower by more than 3 to 4 points relative to the baseline score. At the End of Study timepoint, participants administered the 200 mg dose had a combined Part 2 and Part 3 score that was lower by an average of -8.7 points. By contrast, the combined placebo score increased by an average of +1.7 points, a -10.4 point spread between actively treated versus placebo participants. Patients administered 50 or 100 mg experienced an average change of +1.7 and -1.3 points, respectively, for the combined score. An additional measure of non-motor features of disease utilized the Schwab & England Activities of Daily Life Scale (the S&E scale). The S&E scale was reduced for the 200 mg group by an average of -3.3 points relative to baseline, while the placebos had an average score increase of +3.3 points, a 6.6 point spread between the actively treated participants and the placebos; the 50 mg dose showed no effect for this measure while the 100 mg dose was on average -5.0 points lower relative to baseline. The 201 Trial is a 12-week double-blinded study across three doses plus a placebo group, 1:1:1:1 randomized. The trial is planned to extend every enrolled participant into a 12-month extension study without placebo, but this extension study is not yet implemented. Enrollment is progressing, with 27 of 34 planned sites consenting, screening and enrolling participants. 37 people are either undergoing informed consent, being screened or have been enrolled in the trial, and three participants have completed the full 12-week regimen. The 201 Trial patient portal has been visited by more than 9,000 people since launch in September, 2023, with 5 or more new people becoming pre-qualified daily. Announcement • Aug 25
Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib Inhibikase Therapeutics, Inc. announced that it has developed a novel tablet formulation of IkT-148009, designed to improve drug exposure and overcome existing challenges related to patient use. Major Estimate Revision • Aug 21
Consensus revenue estimates increase by 178%, EPS downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$70.0k to US$180.0k. EPS estimate fell from -US$3.90 to -US$4.39 per share. Biotechs industry in the US expected to see average net income decline 6.6% next year. Consensus price target of US$27.00 unchanged from last update. Share price fell 13% to US$2.17 over the past week. Announcement • Aug 18
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro Inhibikase Therapeutics, Inc. announced the completion of its bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate. The '501' bioequivalence study evaluated IkT-001Pro at four single ascending doses of 300, 400, 500 and 600 mg in 27 healthy subjects ranging in age from 18 to 55, followed by a pivotal phase comparing the 600 mg of IkT-001Pro to 400 mg imatinib Mesylate in 31 healthy volunteers. In total, fifty adverse events were observed following treatment with IkT-001Pro or commercial 400 mg imatinib mesyate, 24 of which were possibly or probably related to the administration of either study drug to the participants in the trial. Imatinib delivered by IkT-001Pro demonstrated a slower rise time to maximum plasma concentration (Tmax) of 6 hours, compared to the 4-hour Tmax of 400 mg imatinib mesyrate, but displayed lower inter-patient variability relative to standard-of-care. Mean and median maximum plasma concentration (Cmax) and overall exposure (AUC0-infinity) were approximately 16% higher for IkT-001Pro relative to 400 mg imatinibmesylate, consistent with higher total imatinib delivery by 600 mg IkT-001Pro. About IkT-001Pro: IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec®?). Imatinib is commonly taken for hematological and gastrointestinal cancers that arise from Abl kinase mutations found in the bone marrow or for gastrointestinal cancers that arise from c-Kit and/or PDGFRa/b mutations in the stomach; c-Kit, PDGFRa/b and Ableson Kinases. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from these in the future. New Risk • Aug 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$20m free cash flow). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Revenue is less than US$1m (US$252k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$27m net loss in 2 years). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$12.1m market cap). Reported Earnings • Aug 16
Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022) Second quarter 2023 results: US$1.11 loss per share (further deteriorated from US$1.10 loss in 2Q 2022). Net loss: US$5.78m (loss widened 25% from 2Q 2022). Revenue is forecast to grow 91% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Announcement • Aug 08
Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Inhibikase Therapeutics, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023 Announcement • Jul 21
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements Inhibikase Therapeutics, Inc. announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq) indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), and that Inhibikase is in compliance with all applicable listing standards. Announcement • Jun 30
Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement Inhibikase Therapeutics, Inc. (Inhibikase or Company) announced that it will effect a 1-for-6 reverse stock split of its common stock. The reverse stock split will become effective at 12:01 A.M June 30, 2023. Inhibikase's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "IKT" and will begin trading on a split-adjusted basis when the market opens on June 30, 2023. The reverse stock split, which was approved by Inhibikase's stockholders on June 23, 2023, is intended to bring the company into compliance with Nasdaq's minimum bid price requirement. The new CUSIP number for the company's common stock following the reverse stock split will be 45719W205. Announcement • Jun 23
Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study Inhibikase Therapeutics, Inc. announced that it has selected the bioequivalent dose of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib (marketed as Gleevec(R)) in patients with Chronic Myelogenous Leukemia (CML) and provided an update on its '501' bioequivalence study. The '501' bioequivalence study has evaluated IkT-001Pro at four single ascending doses of 300, 400, 500 and 600 mg, leading to the selection of 600 mg IkT-001Pro as the bioequivalent dose to 400 mg imatinib mesylate. The pivotal phase of the study was dosed with bioequivalent IkT-001Pro in 31 healthy volunteers; one subject was excluded pre-dose due to aberrant clinical laboratory values. The Company expects to complete the pivotal clinical phase of the study by the end of the second quarter. Following the completion of the '501' trial, Inhibikase will initiate a discussion with the FDA on the parameters for approval of IkT-001Pro under the 505(b)(2) statute. Announcement • Jun 22
Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease Inhibikase Therapeutics, Inc. announced a physician and patient awareness campaign for its Phase 2 '201' program evaluating IkT-148009 as a potentially disease-modifying treatment of Parkinson's disease. Dr. Milton Werner, President & CEO of Inhibikase Therapeutics will present to community neurologists and movement disorder specialists at multiple regional seminars where the Company has activated clinical trial sites. The first two seminars will take place at the Westin Southfield in Southfield, Michigan on June 26 and at the Le Meridién Dallas, the Stoneleigh, in Dallas, Texas on July 11. Reported Earnings • May 17
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022) First quarter 2023 results: US$0.16 loss per share (improved from US$0.18 loss in 1Q 2022). Net loss: US$4.48m (loss narrowed 3.5% from 1Q 2022). Revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Announcement • May 09
Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023 Inhibikase Therapeutics, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023 Announcement • May 06
Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023 Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023, at 09:30 US Eastern Standard Time. Agenda: To elect two directors to the Board of Directors of the Company (the “Board of Directors”) to serve as Class III directors, to serve until the Company’s 2026 annual meeting of stockholders, or until in each case their respective successor is duly elected and qualified; to grant discretionary authority to the Board of Directors to amend our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000 shares; to ratify the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023; to approve an amendment to Article XII of our Certificate of Incorporation to eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof; and to consider and act upon such other matters as may properly come before the meeting or any postponement or adjournment of the meeting. Announcement • Jan 27
Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding Inhibikase Therapeutics, Inc. announced that it has entered into a security purchase agreement for the issuance of 4,883,721 common shares at a price of $0.8599 per share for gross proceeds of $4,200,000 on January 25, 2023. The transaction will include pariticpation from institutional investor. The company will also issue unregistered warrants to purchase up to an aggregate 4,883,721 common shares, at an exercise price of $0.75 per share, is exercisable immediately, and will expire five years following the date of issuance. The transaction is expected to close on or about January 27, 2023, subject to satisfaction of customary closing conditions. The securities to be issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder. Reported Earnings • Nov 16
Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021) Third quarter 2022 results: US$0.18 loss per share (in line with 3Q 2021). Net loss: US$4.49m (flat on 3Q 2021). Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. CEO, President & Director Milton Werner is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. CEO, President & Director Milton Werner is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. CEO, President & Director Milton Werner is the most experienced director on the board, commencing their role in 2010. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 13
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021) Second quarter 2022 results: US$0.18 loss per share. Net loss: US$4.64m (loss widened 76% from 2Q 2021).